RT Journal Article
A1 Tachihara, Motoko
A1 Tsujino, Kayoko
T1 Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer—Reply
JF JAMA Oncology
JO JAMA Oncol
YR 2024
DO 10.1001/jamaoncol.2024.0234
SN 2374-2437
AB In Reply We appreciate Akamatsu for addressing some important points regarding our first prospective study evaluating the efficacy and safety of immunotherapy and concurrent radiotherapy for locally advanced non–small cell lung cancer (NSCLC) without chemotherapy. First, we fully agree with the comments by Akamatsu, suggesting that the inclusion of locally advanced recurrence may overestimate the efficacy outcome. That is why we mentioned in the Discussion that immunoradiotherapy is likely to have a greater effect for postoperative recurrence and stated this in the Limitations. Because postoperative recurrence was allowed in the PACIFIC trial, it was also allowed in the trial. As a result, a large number (25.7%) of postoperative recurrences were enrolled.
RD 5/20/2024
UL https://doi.org/10.1001/jamaoncol.2024.0234